Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Alberta Cancer FoundationJack Ady Cancer Centre launches Alberta's first researcher-led cancer clinical trial outside major urban centresDonor-supported study will evaluate whether prostate cancer radiation treatments can be safely reduced from five sessions to two
- ForgeTrialynx Wins Forge’s DPHARM Idol Disrupt 2026This morning, Trialynx was announced as the winner of DPHARM Idol Disrupt at the 16th annual DPHARM: Disruptive Innovations to Modernize Clinical Research 2026 event. DPHARM is a part of Forge’s Fierce Life Sciences.
- Suvoda earns two PM360 Innovation Awards for Sofia AI assistant and Suvoda AppSuvoda wins two PM360 Innovation Awards for Sofia AI assistant for clinical trials, and the Suvoda App, easing burdens for sites, sponsors, and patients.
- Kaplan Fox Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Losses to Contact the Firm Before November 2, 2026Kaplan Fox announces a securities class action against Hims & Hers Health (NYSE: HIMS) for investors from Aug. 4, 2025 to July 29, 2026.
- National Advertising Division Finds Qualified Saffron Claim Supported; Recommends Alice Mushrooms Discontinue Zen-X Health ClaimNew York, NY – September 16, 2026 – As part of its monitoring program, BBB National Programs’ National Advertising Division examined Alice Mushrooms, LLC’s support for health claims made for its Zen-X mushroom-containing chocolate products. The National Advertising Division (NAD) […]
- National Advertising Division Finds Qualified Saffron Claim Supported; Recommends Alice Mushrooms Discontinue Zen-X Health ClaimAs part of its monitoring program, BBB National Programs’ National Advertising Division examined Alice Mushrooms, LLC’s support for health claims made for its Zen-X mushroom-containing chocolate products. The National Advertising Division (NAD) recommended that Alice Mushrooms modify its Zen-X claim to make clear that the health benefit claim is limited to saffron.
- Avacta Group PLC LONDON andAvacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 TrialAvacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces today that it has achieved clinical proof of mechanism for AVA6103, its next-generation controlled-release pre|CISION® peptide-drug conjugate (PDC) platform in the ongoing phase 1 FOCUS-01 trial.
- MedHQ Appoints Wes Battiste as Executive Vice President of Ambulatory ServicesWESTCHESTER, Ill., September 16, 2026--Avanza + MedHQ, a leading provider of advisory, management, and administrative solutions to hospitals and health systems, ambulatory surgery centers (ASCs), outpatient care providers, and physicians throughout the United States, has appointed Wes Battiste as Executive Vice President of Ambulatory Services.
- ARGOARGO Enhances Behavioral Health CareChain® With AI-Powered Clinical Narrative to Strengthen Medical Necessity DocumentationRICHARDSON, Texas, September 16, 2026--ARGO today announced the release of its new Clinical Narrative enhancement in Behavioral Health CareChain® Version 5.4, designed to help behavioral health organizations streamline utilization review (UR) workflows and improve authorization preparedness, which will strengthen financial growth and sustainability through increased reimbursements. The new feature automatically analyzes multidisciplinary clinical documentation and generates a concise, criteria-f
- MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical TrialMilestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies
- Syneos Health and Tufts CSDD Study Shows Clinical Trial Performance Depends More on Operating Model Design Than Sourcing StrategyData From 13 Leading Pharmaceutical Companies Points to Execution, Governance and Partner Coordination as Key Drivers of Trial Performance
- R1 RCM Holdco Inc.R1 Expands Phare OS with Phare UM, Bringing Real-Time Payer Risk Intelligence to Utilization ManagementThe Guthrie Clinic is Among the First Health Systems Adopting the New AI-enabled Solution to Identify Clinical Status Risk Earlier and Reduce Avoidable Medical Necessity Denials